drugset / Trial / NCT07155369
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Active not recruiting
18 enrolled
The Affiliated Hospital of Xuzhou Medical University
Shanghai Xiniao Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
Timeline
- Start
- 2025-03-18
- Primary completion
- 2026-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UCAR T-cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |